113 related articles for article (PubMed ID: 18339636)
1. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Ananworanich J; Nuesch R; Côté HC; Kerr SJ; Hill A; Jupimai T; Laopraynak N; Saenawat S; Ruxrungtham K; Hirschel B
J Antimicrob Chemother; 2008 Jun; 61(6):1340-3. PubMed ID: 18339636
[TBL] [Abstract][Full Text] [Related]
2. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
3. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
4. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
[TBL] [Abstract][Full Text] [Related]
5. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Hassink EA; van Eck-Smit BL; Borleffs JC; Lange JM; Reiss P
HIV Clin Trials; 2007; 8(5):337-44. PubMed ID: 17956835
[TBL] [Abstract][Full Text] [Related]
6. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Gerschenson M; Kim C; Berzins B; Taiwo B; Libutti DE; Choi J; Chen D; Weinstein J; Shore J; da Silva B; Belsey E; McComsey GA; Murphy RL
J Antimicrob Chemother; 2009 Jun; 63(6):1244-50. PubMed ID: 19321503
[TBL] [Abstract][Full Text] [Related]
8. No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Gayet-Ageron A; Ananworanich J; Jupimai T; Chetchotisakd P; Prasithsirikul W; Ubolyam S; Le Braz M; Ruxrungtham K; Rooney JF; Hirschel B;
J Antimicrob Chemother; 2007 May; 59(5):1034-7. PubMed ID: 17376791
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
10. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Negredo E; Garrabou G; Puig J; Lòpez S; Morén C; Bellido R; Ayen R; Cardellach F; Miró O; Clotet B
Antivir Ther; 2008; 13(2):231-40. PubMed ID: 18505174
[TBL] [Abstract][Full Text] [Related]
11. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
12. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
[No Abstract] [Full Text] [Related]
13. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Dubé MP; Parker RA; Mulligan K; Tebas P; Robbins GK; Roubenoff R; Grinspoon SK
Clin Infect Dis; 2007 Jul; 45(1):120-6. PubMed ID: 17554712
[TBL] [Abstract][Full Text] [Related]
14. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
Casula M; Weverling GJ; Wit FW; Timmermans EC; Stek M; Lange JM; Reiss P
J Infect Dis; 2005 Nov; 192(10):1794-800. PubMed ID: 16235179
[TBL] [Abstract][Full Text] [Related]
16. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
17. Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells.
de Baar MP; de Rooij ER; Smolders KG; van Schijndel HB; Timmermans EC; Bethell R
Antiviral Res; 2007 Oct; 76(1):68-74. PubMed ID: 17628710
[TBL] [Abstract][Full Text] [Related]
18. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Kirian MA; Higginson RT; Fulco PP
Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
[TBL] [Abstract][Full Text] [Related]
19. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
20. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Menezes CN; Crowther NJ; Duarte R; Van Amsterdam D; Evans D; Dickens C; Dix-Peek T; Rassool M; Prinsloo A; Raal F; Sanne I
HIV Med; 2014 Jan; 15(1):3-12. PubMed ID: 23980620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
